The molecular basis of nutritional intervention in multiple sclerosis: A narrative review

Complementary Therapies in Medicine

Volumn 19, Issue 4, 2011, Pages 228-237

  Riccio, P ^a,b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Autoimmunity; Gut microbiota; Inflammation; Multiple sclerosis; NF kB; Nutrition; Omega 3 fatty acids; Polyphenols; PPAR; Transcription factors

Indexed keywords

ACETYLSALICYLIC ACID; CAROTENOID; CATECHIN; CELL NUCLEUS RECEPTOR; CURCUMIN; FISH OIL; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYTYROSOL; METFORMIN; POLYPHENOL; QUERCETIN DERIVATIVE; RESVERATROL; TRANSCRIPTION FACTOR; VITAMIN;

AUTOIMMUNITY; BIOSYNTHESIS; CALORIC RESTRICTION; CATABOLISM; CELL METABOLISM; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; ENZYME REGULATION; EXERCISE; HUMAN; INFLAMMATION; INTESTINE; LOW CALORY DIET; LOW FAT DIET; MILK; MULTIPLE SCLEROSIS; NUTRITION; PROTEIN INTERACTION; REVIEW; WELLBEING;

DISEASE PROGRESSION; ENZYMES; FISH OILS; HUMANS; INFLAMMATION; INTESTINES; MULTIPLE SCLEROSIS; POLYPHENOLS; PREBIOTICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 79961170674     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2011.06.006     Document Type: Review

References (102)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. Lassmann H., Brück W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
3. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007, 8:913-919.
4. Archelos J.J., Hartung H.-P. Pathogenetic roles of autoantibodies in neurological diseases. Trends Neurosci 2000, 23:317-327.
5. Trapp B.D. Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend. Ann Neurol 2004, 55:455-457.
6. Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001, 14:349-357.
7. Schwarz S., Leweling H. Multiple sclerosis and nutrition. Mult Scler 2005, 11:24-32.
8. Farinotti M., Simi S., Di Pietrantonj C., et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2007, 1. [Art. No. CD004192. pub2]. 10.1002/14651858.CD004192.
9. Schwarz S., Knorr C., Geiger H., Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult Scler 2008, 14:1113-1119.
10. Leong E.M., Semple S.J., Angley M., Siebert W., Petkov J., McKinnon R.A. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why?. Complement Ther Med 2009, 17:216-223.
11. WHO and Multiple Sclerosis International Federation Atlas: multiple sclerosis resources in the world 2008; World Health Organisation, Geneva.
12. Thompson A.J. Multiple sclerosis - a global disorder and still poorly managed. Lancet Neurol 2008, 7:1078-1079.
13. Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism. Physiol Rev 2006, 86:465-514.
14. Schrader M., Fahimi H.D. The peroxisome: still a mysterious organelle. Histochem Cell Biol 2008, 129:421-440.
15. Wang K., Wan Y.J. Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) 2008, 233:496-506.
16. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol Disord Drug Targets 2008, 7:536-557.
17. Mitro N., Mak P.A., Vargas L., et al. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445:219-223.
18. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
19. Swank R.L. Multiple sclerosis: a correlation of its incidence with dietary fat. Am J Med Sci 1950, 220:421-430.
20. Swank R.L., Goodwin J.W. Review of MS patient survival on a Swank low saturated fat diet. Nutrition 2003, 19:161-165.
21. Jump D.B., Clarke S.D. Regulation of gene expression by dietary fat. Annu Rev Nutr 1999, 19:63-90.
22. Reichelt K.L., Jensen D. IgA antibodies against gliadin and gluten in multiple sclerosis. Acta Neurol Scand 2004, 110:239-241.
23. Tilg H., Moschen A.R., Kaser A. Obesity and the microbiota. Gastroenterology 2009, 136:1476-1483.
24. Veldhoen M., Hirota K., Westendorf A.M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
25. Guarner F. Hygiene, microbial diversity and immune regulation. Curr Opin Gastroenterol 2007, 23:667-672.
26. Cani P.D., Delzenne N.M. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009, 15:1546-1558.
27. Ochoa-Repáraz J., Mielcarz D.W., Begum-Haque S., Kasper L.H. Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. Ann Neurol 2011, 69:240-247.
28. Yokote H., Miyake S., Croxford J.L., Oki S., Mizusawa H., Yamamura T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008, 173:1714-1723.
29. Wekerle H., Hohlfeld R. Molecular mimicry in multiple sclerosis. N Engl J Med 2003, 349:185-186.
30. Malosse D., Perron H., Sasco A., Seigneurin J.M. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 1992, 11:304-312.
31. Winer S., Astsaturov I., Cheung R.K., et al. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol 2001, 166:4751-4756.
32. Banwell B., Bar-Or A., Cheung R., et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008, 63:98-111.
33. Riccio P. The proteins of the milk fat globule membrane in the balance. Trends Food Sci Technol 2004, 15:458-461.
34. Kennel De March A., De Bouwerie M., Kolopp-Sarda M.N., Faure G.C., Bene M.C., Bernard C.C. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis. J Neuroimmunol 2003, 135:117-125.
35. Guggenmos J., Schubart A.S., Ogg S., et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Neuroimmunol 2004, 1172:661-668.
36. Vojdani A., Campbell A.W., Anyanwu E., Kashanian A., Bock K., Vojdani E. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A'. J Neuroimmunol 2002, 129:168-177.
37. Moss M., Freed D. The cow and the coronary: epidemiology, biochemistry and immunology. Int J Cardiol 2003, 87:203-216.
38. Bravo L. Polyphenols: chemistry, dietary sources, metabolism and nutritional significance. Nutr Rev 1998, 56:317-333.
39. Manach C., Williamson G., Morand C., Scalbert A., Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81(Suppl.):230S-242S.
40. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004, 251:261-268.
41. Zheng L.T., Ryu G.M., Kwon B.M., Lee W.H., Suk K. Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity. Eur J Pharmacol 2008, 588:106-113.
42. Kanashiro A., Souza J.G., Kabeya L.M., Azzolini A.E., Lucisano-Valim Y.M. Elastase release by stimulated neutrophils inhibited by flavonoids: importance of the catechol group. Z Naturforsch [C] 2007, 62:357-361.
43. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008, 585:325-337.
44. Shakibaei M., Harikumar K.B., Aggarwal B.B. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009, 53:115-128.
45. Das S., Das D.K. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007, 6:168-173.
46. Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res 2007, 51:116-134.
47. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008, 269:226-242.
48. Rietjens S.J., Bast A., Haenen G.R.M.M. New insights into controversies on the antioxidant potential of the olive oil antioxidant hydroxytyrosol. J Agric Food Chem 2007, 55:7609-7614.
49. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2008, 41:40-59.
50. Sternberg Z., Chadha K., Lieberman A., et al. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 2008, 205:142-147.
51. Hendriks J.J., de Vries H.E., van der Pol S.M., van den Berg T.K., van Tol E.A., Dijkstra C.D. Flavonoids inhibit myelin phagocytosis by macrophages: a structure activity relationship study. Biochem Pharmacol 2003, 65:877-885.
52. Sagar S.M., Yance D., Wong R.K. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer - Part 1. Curr Oncol 2006, 13:14-26.
53. Sharma V., Mishra M., Ghosh S., et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007, 73:55-63.
54. Russo G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007, 74:533-544.
55. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004, 36:592-604.
56. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 2007, 72:1508-1521.
57. Min Y.D., Choi C.H., Bark H., et al. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res 2007, 56:210-215.
58. Cheng G., Zhang X., Gao D., Jiang X., Dong W. Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model. Neurosci Lett 2009, 451:105-108.
59. Rao A.V., Rao L.G. Carotenoids and human health. Pharmacol Res 2007, 55:207-216.
60. Burton-Freeman B. Postprandial metabolic events and fruit-derived phenolics: review of the science. British J Nutr 2010, 104(Suppl. 3):S1-14.
61. Schmitz G., Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008, 47:147-155.
62. Farooqui A.A., Horrocks L.A., Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007, 101:577-599.
63. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83(Suppl. 6):1505S-1519S.
64. Latronico T., Liuzzi G.M., Rossano R., Fasano A., Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells - implications for complementary multiple sclerosis treatment. Neurochem Res 2007, 32:2184-2193.
65. Liuzzi G.M., Latronico T., Fasano A., Carlone G., Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004, 10:290-297.
66. McCabe A.J., Wallace J.M., Gilmore W.S., McGlynn H., Strain S.J. Docosahexaenoic acid reduces in vitro invasion of renal cell carcinoma by elevated levels of tissue inhibitor of metalloproteinase-1. J Nutr Biochem 2005, 16:17-22.
67. Mehta L.R., Dworkin R.H., Schwid S.R. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 2009, 5:82-92.
68. Shinto L., Marracci G., Baldauf-Wagner S., et al. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids 2009, 80:131-136.
69. Weinstock-Guttman B., Baier M., Park Y., et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005, 73:397-404.
70. Coluccia A., Borracci P., Renna G., et al. Developmental omega-3 supplementation improves motor skills in juvenile-adult rats. Int J Dev Neurosci 2009, 27:599-605.
71. Galland G. Diet and inflammation (invited review). Nutr Clin Pract 2010, 25:634-640.
72. Briet F., Keith M., Leong-Poi H., et al. Triple nutrient supplementation improves survival, infarct size and cardiac function following myocardial infarction in rats. Nutr Metab Cardiovasc Dis 2008, 18:691-699.
73. Suchy J., Chan A., Shea T.B. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-l-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidyl serine reduces oxidative damage to murine brain and improves cognitive performance. Nutr Res 2009, 29:70-74.
74. Piccio L., Stark J.L., Cross A.H. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol 2008, 84:940-948.
75. Fontán-Lozano A., López-Lluch G., Delgado-García J.M., Navas P., Carrión A.M. Molecular bases of caloric restriction regulation of neuronal synaptic plasticity. Mol Neurobiol 2008, 38:167-177.
76. Candelario-Jalil E., de Oliveira A.C., Gräf S., et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflamm 2007, 4:25-37.
77. Sprecher D.L. Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta. Am J Cardiol 2007, 100(11 A):n20-n24.
78. Yasari S., Wang D., Prud'homme D., Jankowski M., Gutkowska J., Lavoie J.M. Exercise training decreases plasma leptin levels and the expression of hepatic leptin receptor-α, -β, and, -e{open} in rats. Mol Cell Biochem 2009, 324:13-20.
79. Nath N., Khan M., Rattan R., et al. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun 2009, 386:16-20.
80. Nath N., Khan M., Paintlia M.K., Hoda M.N., Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 2009, 182:8005-8014.
81. Narkar V.A., Downes M., Yu R.T., et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
82. Reed J.L., De Souza M.J., Williams N.I. Effects of exercise combined with caloric restriction on inflammatory cytokines. Appl Physiol Nutr Metab 2010, 35:573-582.
83. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009, 256:1468-1479.
84. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008, 194:7-17.
85. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
86. Hiremath G., Cettomai D., Baynes M. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009, 15:735-740.
87. Penberthy W.T., Tsunoda I. The importance of NAD in multiple sclerosis. Curr Pharm Des 2009, 15:64-99.
88. Penberthy W.T. Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis. PPAR Res 2009, 2009:853707.
89. Mastronardi F.G., Min W., Wang H., et al. Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1/sonic hedgehog balance. J Immunol 2004, 172:6418-6426.
90. Boosalis M.G. The role of selenium in chronic disease. Nutr Clin Pract 2008, 23:152-160.
91. Morini M., Roccatagliata L., Dell'Eva R., et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 148:146-153.
92. Salinthone S., Schillace R.V., Marracci G.H., Bourdette D.N., Carr D.W. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells. J Neuroimmunol 2008, 199:46-55.
93. Salinthone S., Yadav V., Bourdette D.N., Carr D.W. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008, 8:132-142.
94. Novelli E.L., Santos P.P., Assalin H.B., et al. N-acetylcysteine in high-sucrose diet-induced obesity: energy expenditure and metabolic shifting for cardiac health. Pharmacol Res 2009, 59:74-79.
95. Kidd P.M. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Altern Med Rev 2001, 6:540-566.
96. Pattison D.J., Symmons D.P., Lunt M., et al. Dietary beta-cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. Am J Clin Nutr 2005, 82:451-455.
97. Heneka M.T., Landreth G.E., Hüll M. Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders. Nat Rev Neurol 2007, 3:496-504.
98. Klotz L., Schmidt S., Heun R., Klockgether T., Kolsch H. Association of the PPAR gamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci Lett 2009, 449:81-83.
99. Bernardo A., Bianchi D., Magnaghi V., Minghetti L. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 2009, 68:797-808.
100. Kapadia R., Yi J.-H., Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2009, 13:1813-1826.
101. Silberberg M., Morand C., Mathevon T. The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 2006, 45:88-96.
102. Kieseier B.C., Wiendl H., Hartung H.-P., Stüve O. The future of multiple sclerosis therapy. Pharmacol Res 2009, 60:207-211.